Abstract
Chronic Myeloid Leukemia (CML) is myeloproliferative neoplasm characterized by Philadelphia chromosome which is a balanced translocation between chromosome 9 and 22 in 90% of cases. However, variant cytogenetic still happens in 5-10 % of cases, the importance of which is controversial as well as its response to therapy, prognosis and progression to acute leukemias. Here we report a male patient with CML and variant cytogenetic who responded to low dose of Dasatinib (50 mg daily).
MeSH terms
-
Abnormal Karyotype*
-
Antineoplastic Agents / therapeutic use
-
Bone Marrow / pathology
-
Chromosome Aberrations
-
Chromosomes, Human, Pair 17 / genetics
-
Chromosomes, Human, Pair 17 / ultrastructure
-
Chromosomes, Human, Pair 22 / genetics
-
Chromosomes, Human, Pair 22 / ultrastructure
-
Chromosomes, Human, Pair 9 / genetics
-
Chromosomes, Human, Pair 9 / ultrastructure
-
Dasatinib / therapeutic use
-
Humans
-
In Situ Hybridization, Fluorescence
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
-
Male
-
Middle Aged
-
Molecular Targeted Therapy
-
Protein Kinase Inhibitors / therapeutic use
-
Translocation, Genetic*
Substances
-
Antineoplastic Agents
-
Protein Kinase Inhibitors
-
Dasatinib